These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85. A novel prognostic biomarker: Lai T; Peng T; Li J; Jiang Y; Liu K; Yu W; Yao N; Hu Y; Cao M; Liang J Transl Cancer Res; 2023 May; 12(5):1145-1164. PubMed ID: 37304536 [TBL] [Abstract][Full Text] [Related]
86. Tumor Budding Is an Independent Prognostic Factor in Pancreatic Adenocarcinoma and It Positively Correlates with PD-L1 Expression on Tumor Cells. Pęksa R; Kunc M; Czapiewski P; Piątek M; Hać S; Radecka B; Biernat W Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885065 [TBL] [Abstract][Full Text] [Related]
87. Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis. Guo CL Front Cell Dev Biol; 2022; 10():862791. PubMed ID: 35774228 [TBL] [Abstract][Full Text] [Related]
88. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Wu Q; You L; Nepovimova E; Heger Z; Wu W; Kuca K; Adam V J Hematol Oncol; 2022 Jun; 15(1):77. PubMed ID: 35659268 [TBL] [Abstract][Full Text] [Related]
89. Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Lappano R; Todd LA; Stanic M; Cai Q; Maggiolini M; Marincola F; Pietrobon V Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158804 [TBL] [Abstract][Full Text] [Related]
90. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients. Lv W; Yao Q Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936 [TBL] [Abstract][Full Text] [Related]
91. Melatonin and hyperbaric oxygen therapies suppress colorectal carcinogenesis through pleiotropic effects and multifaceted mechanisms. Li YC; Chen CH; Chang CL; Chiang JY; Chu CH; Chen HH; Yip HK Int J Biol Sci; 2021; 17(14):3728-3744. PubMed ID: 34671196 [TBL] [Abstract][Full Text] [Related]
93. Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. Sukowati CHC; El-Khobar KE; Tiribelli C World J Stem Cells; 2021 Jul; 13(7):795-824. PubMed ID: 34367478 [TBL] [Abstract][Full Text] [Related]
94. Anticipating metastasis through electrochemical immunosensing of tumor hypoxia biomarkers. Muñoz-San Martín C; Gamella M; Pedrero M; Montero-Calle A; Pérez-Ginés V; Camps J; Arenas M; Barderas R; Pingarrón JM; Campuzano S Anal Bioanal Chem; 2022 Jan; 414(1):399-412. PubMed ID: 33635388 [TBL] [Abstract][Full Text] [Related]
95. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Chen J; Jiang CC; Jin L; Zhang XD Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673 [TBL] [Abstract][Full Text] [Related]
96. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Tai YT; Cho SF; Anderson KC Front Immunol; 2018; 9():1822. PubMed ID: 30147691 [TBL] [Abstract][Full Text] [Related]
97. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Barsoum IB; Smallwood CA; Siemens DR; Graham CH Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068 [TBL] [Abstract][Full Text] [Related]
98. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer. Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243 [TBL] [Abstract][Full Text] [Related]
99. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Wen Q; Han T; Wang Z; Jiang S Oncol Lett; 2020 Apr; 19(4):2595-2601. PubMed ID: 32218809 [TBL] [Abstract][Full Text] [Related]